Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro-α silencing and antitumor activity against ovarian cancer

References

• Bahrami B, Hojjat-Farsangi M, Mohammadi H, et al. (2017). Nanoparticles and targeted drug delivery in cancer therapy. Immunol Lett 190:64–83.
   PubMed Web of Science ®Google Scholar
• Barata P, Sood AK, Hong DS. (2016). RNA-targeted therapeutics in cancer clinical trials: current status and future directions. Cancer Treat Rev 50:35–47.
   PubMed Web of Science ®Google Scholar
• de Wolf HK, Snel CJ, Verbaan FJ, et al. (2007). Effect of cationic carriers on the pharmacokinetics and tumor localization of nucleic acids after intravenous administration. Int J Pharm 331:167–75.
   PubMed Web of Science ®Google Scholar
• Debus H, Baumhof P, Probst J, Kissel T. (2010). Delivery of messenger RNA using poly(ethylene imine)-poly(ethylene glycol)-copolymer blends for polyplex formation: biophysical characterization and in vitro transfection properties. J Control Release 148:334–43.
   PubMed Web of Science ®Google Scholar
• Emons G, Gorchev G, Sehouli J, et al. (2014). Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5). Gynecol Oncol 133:427–32.
   PubMed Web of Science ®Google Scholar
• Engel JB, Tinneberg HR, Rick FG, et al. (2016). Targeting of peptide cytotoxins to LHRH receptors for treatment of cancer. Curr Drug Targets 17:488–94.
   PubMed Web of Science ®Google Scholar
• Fan L, Chen J, Zhang X, et al. (2014). Follicle-stimulating hormone polypeptide modified nanoparticle drug delivery system in the treatment of lymphatic metastasis during ovarian carcinoma therapy. Gynecol Oncol 135:125–32.
   PubMed Web of Science ®Google Scholar
• Feng L, Yang X, Shi X, et al. (2013). Polyethylene glycol and polyethylenimine dual-functionalized nano-graphene oxide for photothermally enhanced gene delivery. Small 9:1989–97.
   PubMed Web of Science ®Google Scholar
• Feng Y, Zhu S, Antaris AL, et al. (2017). Live imaging of follicle stimulating hormone receptors in gonads and bones using near infrared II fluorophore. Chem Sci 8:3703–11.
   PubMed Web of Science ®Google Scholar
• Feng Z, Wen H, Bi R, et al. (2016). A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci Rep 6:25408.
   PubMed Web of Science ®Google Scholar
• Ghanghoria R, Kesharwani P, Tekade RK, Jain NK. (2016). Targeting luteinizing hormone-releasing hormone: a potential therapeutics to treat gynecological and other cancers. J Control Release 269:277–301.
   PubMed Web of Science ®Google Scholar
• Gvozdeva OV, Prassolov VS, Zenkova MA, et al. (2016). Silencing of inducible immunoproteasome subunit expression by chemically modified siRNA and shRNA. Nucleosides Nucleotides Nucleic Acids 35:389–403.
   PubMed Web of Science ®Google Scholar
• Hong H, Yan Y, Shi S, et al. (2015). PET of follicle-stimulating hormone receptor: broad applicability to cancer imaging. Mol Pharm 12:403–10.
   PubMed Web of Science ®Google Scholar
• Hong S, Zhang X, Chen J, et al. (2013). Targeted gene silencing using a follicle-stimulating hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro. J Ovarian Res 6:80.
   PubMed Web of Science ®Google Scholar
• Kaczmarek JC, Kowalski PS, Anderson DG. (2017). Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med 9:60.
   PubMed Web of Science ®Google Scholar
• Lam JK, Chow MY, Zhang Y, Leung SW. (2015). siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids 4:e252.
   PubMedGoogle Scholar
• Lee CW, Guo L, Matei D, Stantz K. (2015). Development of follicle-stimulating hormone receptor binding probes to image ovarian xenografts. J Biotechnol Biomater 5:198.
   PubMedGoogle Scholar
• Li X, Taratula O, Taratula O, et al. (2017). LHRH-targeted drug delivery systems for cancer therapy. Mini Rev Med Chem 17:258–67.
   PubMed Web of Science ®Google Scholar
• Mao S, Neu M, Germershaus O, et al. (2006). Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/SiRNA polyplexes. Bioconjug Chem 17:1209–18.
   PubMed Web of Science ®Google Scholar
• Modi DA, Sunoqrot S, Bugno J, et al. (2014). Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells. Nanoscale 6:2812–20.
   PubMed Web of Science ®Google Scholar
• Ngamcherdtrakul W, Castro DJ, Gu S, et al. (2016). Current development of targeted oligonucleotide-based cancer therapies: perspective on HER2-positive breast cancer treatment. Cancer Treat Rev 45:19–29.
   PubMed Web of Science ®Google Scholar
• Pan D, Liu G, Xu Y, et al. (2017). PET imaging of FSHR expression in tumors with 68Ga-Labeled FSH1 Peptide. Contrast Media Mol Imaging 2017:2674502.
   PubMed Web of Science ®Google Scholar
• Papadimitriou K, Kountourakis P, Kottorou AE, et al. (2016). Follicle-stimulating hormone receptor (FSHR): a promising tool in oncology? Mol Diagn Ther 20:523–30.
   PubMed Web of Science ®Google Scholar
• Park MR, Han KO, Han IK, et al. (2005). Degradable polyethylenimine-alt-poly(ethylene glycol) copolymers as novel gene carriers. J Control Release 105:367–80.
   PubMed Web of Science ®Google Scholar
• Perales-Puchalt A, Svoronos N, Rutkowski MR, et al. (2017). Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res 23:441–53.
   PubMed Web of Science ®Google Scholar
• Shah V, Taratula O, Garbuzenko OB, et al. (2013). Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 19:6193–204.
   PubMed Web of Science ®Google Scholar
• Shi J, Kantoff PW, Wooster R, Farokhzad OC. (2017). Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 17:20–37.
   PubMed Web of Science ®Google Scholar
• Smith RJ, Beck RW, Prevette LE. (2015). Impact of molecular weight and degree of conjugation on the thermodynamics of DNA complexation and stability of polyethylenimine-graft-poly(ethylene glycol) copolymers. Biophys Chem 203–204:12–21.
   PubMed Web of Science ®Google Scholar
• Sun X, Zhang N. (2010). Cationic polymer optimization for efficient gene delivery. Mini Rev Med Chem 10:108–25.
   PubMed Web of Science ®Google Scholar
• Taratula O, Patel M, Schumann C, et al. (2015). Phthalocyanine-loaded graphene nanoplatform for imaging-guided combinatorial phototherapy. Int J Nanomedicine 10:2347–62.
   PubMed Web of Science ®Google Scholar
• Urbanska K, Stashwick C, Poussin M, Powell DJ. (2015). Follicle-stimulating hormone receptor as a target in the redirected T-cell therapy for cancer. Cancer Immunol Res 3:1130–7.
   PubMed Web of Science ®Google Scholar
• Wang D, Sun H, Wei J, et al. (2017). CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res 77:3655–65.
   PubMed Web of Science ®Google Scholar
• Yang G, Rosen DG, Zhang Z, et al. (2006). The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci USA103:16472–7.
   PubMed Web of Science ®Google Scholar
• Young SW, Stenzel M, Yang JL. (2016). Nanoparticle-siRNA: a potential cancer therapy? Crit Rev Oncol Hematol 98:159–69.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Kang Y, et al. (2013). Targeted paclitaxel nanoparticles modified with follicle-stimulating hormone β 81-95 peptide show effective antitumor activity against ovarian carcinoma. Int J Pharm 453:498–505.
   PubMed Web of Science ®Google Scholar
• Zhang X, Pan SR, Hu HM, et al. (2008). Poly(ethylene glycol)-block-polyethylenimine copolymers as carriers for gene delivery: effects of PEG molecular weight and PEGylation degree. J Biomed Mater Res A 84:795–804.
   PubMed Web of Science ®Google Scholar
• Zhang X, Xu C. (2011). Application of reproductive hormone peptides for tumor targeting. Curr Pharm Biotechnol 12:1144–52.
   PubMed Web of Science ®Google Scholar
• Zhang XY, Chen J, Zheng YF, et al. (2009). Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69:6506–14.
   PubMed Web of Science ®Google Scholar